On November 16, 2026, Jaguar Health, Inc. (NASDAQ: JAGX) reported its financial results for the third quarter of 2026. The company announced a significant reduction in its outstanding debt balance of $10.1 million during the quarter. Jaguar also provided an update on its development pipeline, stating that the rare disease intestinal failure program for microvillus inclusion disease (MVID) and short bowel syndrome is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027.

Financial results for the three months ended September 30, 2026, showed a total net revenue of $2.34 million, a decrease of $740,000 or 24.0% compared to the same period in 2025. This decline was driven by a decrease in product revenue, which fell to approximately $0.55 million from $3.04 million in the prior year. The company noted that the number of Mytesi bottles sold increased significantly in 2026, but commercial costs were substantially decreased.

License and grant revenue for the quarter was $1.79 million, a substantial increase from $42,000 in the prior year. This revenue is primarily attributed to a U.S. commercial licensing agreement with Woodward Specialty, LLC, an affiliate of Future Pak, LLC. Under this agreement, Future Pak is the exclusive U.S. marketer for Mytesi and Canalevia-CA1, while Jaguar remains the manufacturer. The company recognized license revenues related to an initial $16 million upfront payment and a $3 million payment for the early termination of a Buy-Back Option in the first quarter of 2026. Additionally, Jaguar recognized license fees of $42,000 in Q3 2026 from a securities purchase agreement with a European partner.

For the nine months ended September 30, 2026, the company reported a net loss of $5.83 million, compared to a net loss of $9.65 million in the same period in 2025. The loss from operations decreased to $6.02 million from $7.24 million in the prior year. The company attributes this improvement to a reduction in operating expenses of approximately $2.0 million, largely due to the Future Pak licensing agreement, which led to the dissolution of the Jaguar/Napo Sales and Marketing Group as of January 12, 2026.

Research and development expenses decreased by approximately $0.1 million to $3.6 million, while sales and marketing expenses dropped to approximately $51,000 from $2.0 million in the prior year. The company also reported a gain on the extinguishment of debt of $0.6 million in Q3 2026, primarily attributable to the repayment and cancellation of the Streeterville New Note following an exchange transaction in which the company issued shares of common stock.